Mineralys Therapeutics(US:MLYS) Globenewswire·2025-12-12 16:00Core Insights - Mineralys Therapeutics' Phase 3 Launch-HTN trial of lorundrostat for uncontrolled hypertension was recognized as one of the most impactful studies of 2025 by JAMA [1][2][3] - The trial demonstrated significant reductions in systolic blood pressure and a favorable safety profile, addressing a critical need for patients with treatment-resistant hypertension [3][4][6] Company Overview - Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and related conditions, including chronic kidney disease and obstructive sleep apnea [13] - The company's lead product, lorundrostat, is a highly selective aldosterone synthase inhibitor designed to target the root cause of hypertension by reducing aldosterone levels [11][12] Clinical Trial Details - The Launch-HTN trial involved 1,083 participants with uncontrolled or treatment-resistant hypertension, evaluating the efficacy and safety of lorundrostat when added to existing antihypertensive treatments [3][8] - Key findings included a 16.9 mmHg reduction in systolic blood pressure at Week 6 and a 19.0 mmHg reduction at Week 12, with statistically significant results (p-value < 0.0001) [6][8] - The trial's diverse participant demographics included a high proportion of women, Black or African American individuals, and elderly participants [3] Health Impact - Hypertension is a significant public health issue, contributing to over 685,000 deaths in the U.S. in 2022 and resulting in an estimated economic burden of $219 billion in 2019 [9][10] - Less than 50% of hypertension patients achieve their blood pressure goals with current medications, highlighting the need for new treatment options like lorundrostat [10] Future Developments - Lorundrostat is currently being evaluated in the ongoing Transform-HTN trial for long-term safety and efficacy, as well as in the Explore-OSA trial for its effects on obstructive sleep apnea [5][7]